On September 2, 2014, the first potential subjects were screened for our Canadian study of MDMA-assisted psychotherapy for PTSD. Led by Principal Investigator Ingrid Pacey, M.D., and co-therapists Donna Dryer, M.D., and Richard Yensen , Ph.D., in Vancouver, B.C., this study will treat up to 12 subjects with chronic, treatment-resistant PTSD from any cause. On August 12, the study was highlighted in an article on Canada.com. MAPS is sponsoring this study in association with MAPS Canada, the first and only Canadian organization dedicated to psychedelic research and education, now able to receive tax-deductible contributions in Canada. "After an incredibly long process of study approval and start-up, it is wonderful to see all of our hard work come to fruition," said Amy Emerson, MAPS Director of Clinical Research. "The addition of this study team will give us experience with a new therapy team and a chance to compare with results from our other studies."